isoniazid and Tuberculosis, Multidrug-Resistant studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Research Excerpts

Excerpt	Relevance	Reference
"Tuberculosis patients "resistant to isoniazid and susceptible to rifampicin (Hr-TB)" remain neglected, despite a high burden and poor outcomes."	9.41	Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. ( Alaverdyan, S; Gadoev, J; Kumar, A; Nabirova, D; Parpieva, N; Sayfutdinov, Z; Sultanov, S; Turaev, L, 2021)
"The drug isoniazid (INH) is a key component of global tuberculosis (TB) control programmes."	8.95	Isoniazid-resistant tuberculosis: a cause for concern? ( Jenkins, HE; Lipman, MC; McHugh, TD; Stagg, HR, 2017)
"In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation."	8.83	Isoniazid preventive therapy and risk for resistant tuberculosis. ( Balcells, ME; Godfrey-Faussett, P; Grant, AD; Thomas, SL, 2006)
"Isoniazid-monoresistant tuberculosis (HR-TB) requires early diagnosis and adapted treatment to achieve optimal outcomes."	8.12	Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. ( Bachir, M; Billard-Pomares, T; Chiesi, S; Guglielmetti, L; Jaffré, J; Langris, H; Lemaître, N; Pourcher, V; Robert, J; Schramm, F; Tunesi, S, 2022)
"TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China."	8.12	Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022)
"Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis."	7.96	Isoniazid-resistant tuberculosis: A problem we can no longer ignore. ( Pai, M; Sulis, G, 2020)
"Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes."	7.96	Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study. ( Chang, J; Choi, JS; Chung, KS; Jung, JY; Kang, YA; Kim, EY; Kim, SY; Kim, YS; Kwak, SH; Lee, EH; Lee, SH; Leem, AY; Park, MS, 2020)
"Isoniazid resistant tuberculosis is the most prevalent type of resistance in Swaziland and over two-thirds of the isoniazid resistant tuberculosis patients are tuberculosis and human immunodeficiency virus co-infected."	7.91	Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. ( Chien, LY; Dlamini, NC; Ji, DD, 2019)
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children."	7.88	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018)
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease."	7.85	Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017)
"The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is centred in North London, with over 400 cases diagnosed since 1995."	7.83	Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance. ( Karlikowska, M; Lipman, M; McHugh, TD; Satta, G; Shorten, RJ; Witney, AA, 2016)
"The expected increase in drug-resistant tuberculosis due to large-scale preventive treatment in people living with HIV calls for reconsidering the "double use" of isoniazid for prophylaxis and curative treatment (Mills et al."	7.79	For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance. ( Cobelens, FG, 2013)
"Mutations at codons 526 and 531 in the rpoB gene and at 315 in the katG gene are considered diagnostic markers for resistance to rifampin and isoniazid in tuberculosis."	7.78	Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. ( Cuellar, A; Cuevas-Cordoba, B; Enciso, A; Enciso, L; Zenteno-Cuevas, R, 2012)
"Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0."	7.78	Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. ( Arias, F; Barrera, L; Boulahbal, F; Cavanaugh, JS; Cegielski, JP; Coulter, C; Drobniewski, F; Kim, H; Kurbatova, EV; Lumb, R; Martín-Casabona, N; Metchock, B; Richter, E; Santos Silva, A; Shah, NS; Van Deun, A; Wright, A; Zemanova, I, 2012)
"We conducted a case–control study to examine risk factors for isoniazid-monoresistant Mycobacterium tuberculosis in an ongoing outbreak in London."	7.77	Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. ( Altass, L; Anaraki, S; Bothamley, G; Brailsford, S; Carless, J; Charlett, A; Lipman, M; Lozewicz, S; Maguire, H; Yates, M; Yates, S, 2011)
"We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa."	7.77	Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. ( Jacobson, KR; Murray, MB; Streicher, EM; Theron, D; Victor, TC; Warren, RM, 2011)
"Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)."	7.77	Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011)
"To design and standardize an in-house reverse line blot hybridization (RLBH) assay for the accurate identification of 15 clinically relevant species of mycobacteria and for the detection of drug resistance to rifampin (RIF), isoniazid (INH), and streptomycin (STR) in Mycobacterium tuberculosis complex (MTB)."	7.75	Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex. ( Mehta, A; Rodrigues, C; Shenai, S, 2009)
"To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases."	7.74	[Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. ( Aono, A; Ito, K; Ogata, H; Wada, M; Yoshiyama, T, 2007)
"National tuberculosis treatment guidelines suggest a regimen of 2RZE/10RE for the treatment of isoniazid resistant organisms."	7.71	Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? ( Green, RM; Horsfield, N; Ormerod, LP, 2001)
"To determine the value of ahpC promoter mutations for the rapid prediction of isoniazid resistance, this genomic region was characterized in 50 isoniazid-resistant and 12 isoniazid-sensitive Mycobacterium tuberculosis isolates."	7.70	Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. ( Bretzel, G; Feldmann, K; Löscher, T; Rifai, M; Rinder, H; Rüsch-Gerdes, S; Thomschke, A, 1998)
"We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents."	7.69	Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994)
"Isoniazid is a first-line pro-drug that requires activation through an enzyme called catalase peroxidase, but is subject to widespread resistance, driven by mutations in katG and inhA genes and other loci with compensatory effects (e."	5.91	Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. ( Ahmad, S; Alam, J; Ali, S; Campino, S; Clark, TG; Khan, AS; Khan, MT; Khan, TA; Khattak, B; Mohammad, N; Napier, G; Phelan, JE; Qasim, M, 2023)
"Pyrazinamide resistance was found in 6/80 (7."	5.72	Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022)
"Drug resistant tuberculosis is increasing world-wide."	5.48	Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. ( Kirschner, DE; Linderman, JJ; Pienaar, E, 2018)
"Tuberculosis patients "resistant to isoniazid and susceptible to rifampicin (Hr-TB)" remain neglected, despite a high burden and poor outcomes."	5.41	Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. ( Alaverdyan, S; Gadoev, J; Kumar, A; Nabirova, D; Parpieva, N; Sayfutdinov, Z; Sultanov, S; Turaev, L, 2021)
"Resectional lung surgery combined with isoniazid- and rifampin-based anti-tuberculous chemotherapy can be an effective treatment strategy for patients with well-localized, cavitary pulmonary MDR-TB and XDR-TB."	5.35	Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. ( Cho, JS; Kang, H; Kim, JH; Park, SK; Smego, RA, 2009)
" Loop-mediated isothermal amplification and Au-Nanoprobe showed 100% sensitivity and specificity in detecting rifampicin and isoniazid resistance."	5.12	Combining LAMP and Au-Nanoprobe to detect INH-RIF resistance accurately in tuberculosis: an evidence-based review. ( Ariq, H; Habiburrahman, M; Handayani, RRD, 2021)
"In patients with newly diagnosed tuberculosis, diabetes is associated with isoniazid resistance."	5.05	The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis. ( Huang, D; Liang, Z; Wang, Y, 2020)
"The drug isoniazid (INH) is a key component of global tuberculosis (TB) control programmes."	4.95	Isoniazid-resistant tuberculosis: a cause for concern? ( Jenkins, HE; Lipman, MC; McHugh, TD; Stagg, HR, 2017)
"After the introduction of isoniazid and rifampicin, the second one discovered in the Lepetit Research Laboratories (Milan, Italy), under the supervision of Professor Piero Sensi, tuberculosis (TB) was considered an illness of the past."	4.90	Trends in discovery of new drugs for tuberculosis therapy. ( Pasca, MR; Riccardi, G, 2014)
"In this systematic review, we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months, adding rifampicin to isoniazid regimens, benefits of different regimens, chemotherapy for <6 months, daily chemotherapy, direct observation treatment, intermittent chemotherapy for 6 months or longer, isoniazid, low-level laser therapy for pulmonary tuberculosis, regimens containing quinolones, rifampicin plus isoniazid, substituting rifampicin with ethambutol in the continuous phase, and support mechanisms for directly observed treatment."	4.87	Tuberculosis (HIV-negative people). ( Eisenhut, M; Ziganshina, LE, 2011)
"In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months; adding rifampicin to isoniazid regimens; benefits of different regimens; chemotherapy for less than 6 months; daily chemotherapy; direct observation treatment; intermittent chemotherapy for 6 months or longer; isoniazid; low-level laser therapy for pulmonary tuberculosis; regimens containing quinolones; rifampicin plus isoniazid; substituting rifampicin with ethambutol in the continuous phase; and support mechanisms for directly observed treatment."	4.85	Tuberculosis (HIV-negative people). ( Garner, P; Ziganshina, LE, 2009)
"In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation."	4.83	Isoniazid preventive therapy and risk for resistant tuberculosis. ( Balcells, ME; Godfrey-Faussett, P; Grant, AD; Thomas, SL, 2006)
"Resistance to isoniazid (INH) and rifampicin (RIF) first-line drugs in Mycobacterium tuberculosis (Mtb), together called multi-drug resistance, threatens tuberculosis control."	4.31	Large-scale genomic analysis of Mycobacterium tuberculosis reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis. ( Campino, S; Clark, TG; Napier, G; Phelan, JE, 2023)
" The BD MAX™ multidrug resistant (MDR)-TB assay (BD MAX™) has demonstrated high sensitivity and specificity for the detection of the Mycobacterium tuberculosis complex (MTBC) as well as resistance to INH and Rifampin (RIF) in pulmonary specimens but has not been rigorously assessed in extrapulmonary samples."	4.31	An analytic feasibility study of the BD MAX™ MDR-TB assay for testing of non-sputum specimens for detection of the Mycobacterium tuberculosis complex (MTBC) and isoniazid (INH) and rifampin (RIF) resistance. ( Armstrong, D; Fisher, S; Parrish, N; Totten, M, 2023)
"Isoniazid-monoresistant tuberculosis (HR-TB) requires early diagnosis and adapted treatment to achieve optimal outcomes."	4.12	Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. ( Bachir, M; Billard-Pomares, T; Chiesi, S; Guglielmetti, L; Jaffré, J; Langris, H; Lemaître, N; Pourcher, V; Robert, J; Schramm, F; Tunesi, S, 2022)
"TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China."	4.12	Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022)
"We estimated costs of managing different forms of tuberculosis (TB) across Canada by conducting a retrospective chart review and cost assessment of patients treated for TB infection, drug-susceptible TB (DS TB), isoniazid-resistant TB, or multidrug-resistant TB (MDR TB) at 3 treatment centers."	4.12	Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016. ( Brode, SK; Campbell, JR; Chiang, LY; Jamieson, F; Johnston, JC; Khadawardi, H; Mah, HK; Nsengiyumva, P; Oxlade, O; Rasberry, H; Rea, E; Romanowski, K; Sabur, NF; Sander, B; Schwartzman, K; Uppal, A, 2022)
"Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis."	3.96	Isoniazid-resistant tuberculosis: A problem we can no longer ignore. ( Pai, M; Sulis, G, 2020)
"Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes."	3.96	Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study. ( Chang, J; Choi, JS; Chung, KS; Jung, JY; Kang, YA; Kim, EY; Kim, SY; Kim, YS; Kwak, SH; Lee, EH; Lee, SH; Leem, AY; Park, MS, 2020)
"Isoniazid resistant tuberculosis is the most prevalent type of resistance in Swaziland and over two-thirds of the isoniazid resistant tuberculosis patients are tuberculosis and human immunodeficiency virus co-infected."	3.91	Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. ( Chien, LY; Dlamini, NC; Ji, DD, 2019)
" The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)."	3.91	Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019)
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children."	3.88	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018)
" The respective sensitivity and specificity were 84% and 100% for isoniazid (INH); 82% and 100% for rifampin (RIF); 67% and 100% for amikacin (AK); and both 100% for ofloxacin (OFX)."	3.88	Evaluation of Nitrate Reductase Assay for Early Detection of Multi and Extensively Drug Resistance Tuberculosis in our Setup. ( Ahmed, P; Gardezi, AH; Ikram, AI; Lalani, FK; Satti, ML; Zaman, G, 2018)
" Computer-aided clinical trial simulations have suggested that isoniazid and rifampin pharmacokinetic variability best explained poor outcomes."	3.86	Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. ( Gumbo, T; Pasipanodya, JG; Srivastava, S, 2012)
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease."	3.85	Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017)
"The sensitivity and specificity of MTBDRplus in detecting isoniazid (INH) resistance were 96."	3.85	Performance of MTBDRplus assay in detecting multidrug resistant tuberculosis at hospital level. ( Ameni, G; Assefa, M; Demisse, D; Getachew, Z; Kebede, A; Tedla, Y; Yenew, B, 2017)
"The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is centred in North London, with over 400 cases diagnosed since 1995."	3.83	Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance. ( Karlikowska, M; Lipman, M; McHugh, TD; Satta, G; Shorten, RJ; Witney, AA, 2016)
"The expected increase in drug-resistant tuberculosis due to large-scale preventive treatment in people living with HIV calls for reconsidering the "double use" of isoniazid for prophylaxis and curative treatment (Mills et al."	3.79	For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance. ( Cobelens, FG, 2013)
" Minimal inhibitory concentrations (MICs) of isoniazid (INH), rifampicin (RMP) and levofloxacin (LVX) from 169 DR tuberculosis (TB) isolates, 78 of them monoresistant to INH, 13 to RMP, 7 to LVX, and 71 MDR-TB, were determined."	3.79	Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. ( Cataldi, AA; Di Giulio, AB; Imperiale, BR; Morcillo, NS; Zumárraga, MJ, 2013)
" tuberculosis by MTBDRplus, this assay's sensitivity and specificity for rifampin resistance were 85."	3.78	Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. ( Beylis, N; Chihota, VN; Churchyard, GJ; Dorman, SE; Fielding, KL; Grant, AD; Lewis, JJ; Mathema, B; van der Meulen, M, 2012)
"Mutations at codons 526 and 531 in the rpoB gene and at 315 in the katG gene are considered diagnostic markers for resistance to rifampin and isoniazid in tuberculosis."	3.78	Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. ( Cuellar, A; Cuevas-Cordoba, B; Enciso, A; Enciso, L; Zenteno-Cuevas, R, 2012)
"Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0."	3.78	Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. ( Arias, F; Barrera, L; Boulahbal, F; Cavanaugh, JS; Cegielski, JP; Coulter, C; Drobniewski, F; Kim, H; Kurbatova, EV; Lumb, R; Martín-Casabona, N; Metchock, B; Richter, E; Santos Silva, A; Shah, NS; Van Deun, A; Wright, A; Zemanova, I, 2012)
"In Uganda, isoniazid plus ethambutol is used for 6 months (6HE) during the continuation treatment phase of new tuberculosis (TB) cases."	3.78	Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis. ( Castelnuovo, B; Hermans, SM; Kuznik, A; Lamorde, M; Manabe, YC; Mullins, CD, 2012)
"In the present study, sensitivity and specificity of the phage assay when compared to proportion method were in the range of 97 to 100 per cent for all the drugs except for ciprofloxacin for which it was 93 and 96 per cent, respectively."	3.78	In-house, simple & economical phage technique for rapid detection of rifampicin, isoniazid, ethambutol, streptomycin & ciprofloxacin drug resistance using Mycobacterium tuberculosis isolates. ( Chitnis, DS; Hemvani, N; Patidar, V, 2012)
"We conducted a case–control study to examine risk factors for isoniazid-monoresistant Mycobacterium tuberculosis in an ongoing outbreak in London."	3.77	Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. ( Altass, L; Anaraki, S; Bothamley, G; Brailsford, S; Carless, J; Charlett, A; Lipman, M; Lozewicz, S; Maguire, H; Yates, M; Yates, S, 2011)
" We show that Mtb continues to acquire mutations during disease latency, which may explain why isoniazid monotherapy for latent tuberculosis is a risk factor for the emergence of isoniazid resistance."	3.77	Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. ( Chase, MR; Flynn, JL; Ford, CB; Fortune, SM; Galagan, J; Iartchouk, O; Ioerger, TR; Lin, PL; Lipsitch, M; Mohaideen, N; Sacchettini, JC; Shah, RR, 2011)
"We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa."	3.77	Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. ( Jacobson, KR; Murray, MB; Streicher, EM; Theron, D; Victor, TC; Warren, RM, 2011)
"Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)."	3.77	Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011)
"The objective of this study was to evaluate the resistance to isoniazid (INH), rifampicin (RIF), streptomycin (STR) and ethambutol (EMB), with the Canetti's proportions method (PM) and the nitrate reductase assay (NRA) of 59 clinical strains of Mycobacterium tuberculosis, isolated in the period of august 2005 to december 2006, in Sucre state, Venezuela."	3.76	[Susceptibility of M. tuberculosis to antituberculosis drugs as determined by two methods, in Sucre state, Venezuela]. ( Bello, T; Chirinos, G; De Donato, M; de Waard, JH; Mendoza, R; Takiff, H, 2010)
"To design and standardize an in-house reverse line blot hybridization (RLBH) assay for the accurate identification of 15 clinically relevant species of mycobacteria and for the detection of drug resistance to rifampin (RIF), isoniazid (INH), and streptomycin (STR) in Mycobacterium tuberculosis complex (MTB)."	3.75	Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex. ( Mehta, A; Rodrigues, C; Shenai, S, 2009)
"To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases."	3.74	[Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. ( Aono, A; Ito, K; Ogata, H; Wada, M; Yoshiyama, T, 2007)
"The sensitivity and specificity of the resazurin test were studied in 77 strains and were respectively 95% and 97."	3.74	Evaluation of the resazurin assay for the detection of multidrug-resistant Mycobacterium tuberculosis in Madagascar. ( Martin, A; Portaels, F; Ramarokoto, H; Rasolofo Razanamparany, V; Rasolonavalona, T; Ravololonandriana, P; Rivoire, N, 2007)
"To investigate the prognosis of isoniazid (H) resistant rifampicin (R) susceptible tuberculosis cases with emphasis on the risk factors of developing MDR."	3.73	[Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis]. ( Aono, A; Ito, K; Ogata, H; Wada, M; Yoshiyama, T, 2005)
" Specimens were cultured for Mycobacterium tuberculosis and tested for resistance to isoniazid, rifampicin, ethambutol, and streptomycin."	3.72	Control of anti-tuberculosis drug resistance in Botswana. ( Binkin, NJ; Kenyon, TA; Mallon, V; Moeti, TL; Mwasekaga, MJ; Talbot, EA, 2003)
"The capacity to generate a chronic and persistent infection in the experimental murine model of tuberculosis induced aerogenically by a low-dose inoculum was determined in eight isoniazid-resistant clinical strains of Mycobacterium tuberculosis showing different catalase-peroxidase (C-P) activities."	3.72	Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. ( Amat, I; Ariza, A; Ausina, V; Cardona, PJ; Díaz, J; Gordillo, S; Llatjós, R; Lonca, J; Pallarés, A; Vilaplana, C, 2003)
"To study the probability of acquiring drug resistance to isoniazid (H) and rifampicin (R) on recurrence after treatment success, default and failure, among sputum smear-positive pulmonary tuberculosis (TB) patients treated with standardised short-course chemotherapy."	3.72	Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. ( Mori, T; Nampaisan, O; Palittapongarnpim, P; Rhiengtong, D; Supawitkul, S; Uthaivorawit, W; Yanai, H; Yoshiyama, T, 2004)
"National tuberculosis treatment guidelines suggest a regimen of 2RZE/10RE for the treatment of isoniazid resistant organisms."	3.71	Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? ( Green, RM; Horsfield, N; Ormerod, LP, 2001)
"Standard drug susceptibility testing by the proportion method against streptomycin (S), isoniazid (H), rifampicin (R), and ethambutol (E) was performed with Mycobacterium tuberculosis isolated from 916 new cases and 456 previously treated cases."	3.71	Sample survey of drug-resistant tuberculosis in Henan, China, 1996. ( Ding, D; Duanmu, HJ; Li, D; Peng, YL; Song, H; Wang, G; Wang, L; Xing, J; Zhang, G; Zhang, L; Zhang, Z, 2002)
"9 percent of Mycobacterium tuberculosis strains were resistant to at least one drug (range, 2 to 41 percent); resistance to isoniazid (7."	3.70	Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. ( Binkin, N; Bustreo, F; Chaulet, P; Cohn, DL; Kim, SJ; Lambregts-van Weezenbeek, CS; Laszlo, A; Nunn, P; Pablos-Méndez, A; Raviglione, MC; Rieder, HL, 1998)
"To determine the value of ahpC promoter mutations for the rapid prediction of isoniazid resistance, this genomic region was characterized in 50 isoniazid-resistant and 12 isoniazid-sensitive Mycobacterium tuberculosis isolates."	3.70	Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. ( Bretzel, G; Feldmann, K; Löscher, T; Rifai, M; Rinder, H; Rüsch-Gerdes, S; Thomschke, A, 1998)
"We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents."	3.69	Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994)
"The duration of the standard treatment for tuberculosis can be shortened to four months but this treatment regimen is also based on rifapentine, in addition to isoniazid, pyrazinamide, and moxifloxacin."	3.01	[Treatment of tuberculosis: what is new?] ( Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E, 2023)
"Additionally, treating tuberculosis with antibiotics also poses a serious risk of hepatotoxicity in the patient's body."	3.01	Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. ( Ahmad, W; Alharbi, JN; Alomary, MN; Alyahya, SA; Ansari, MA; Ansari, SMA; Ather, H; Hani, U; Imran, MA; Islam, N; Jamous, YF; Shoaib, S; Wahab, S, 2023)
"Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially."	2.90	Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. ( Ahn, H; Cho, YJ; Choi, HS; Choi, SM; Hahn, S; Han, J; Heo, EY; Hwang, YR; Jeong, I; Jo, YS; Joh, JS; Ki, J; Kim, DK; Kim, H; Kim, HS; Kim, J; Kim, SJ; Kwak, N; Lee, CH; Lee, J; Lee, JH; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, SM; Lee, YJ; Lim, JN; Park, JH; Park, JS; Park, SS; Park, YS; Song, T; Yim, JJ; Yoon, HI, 2019)
" 501 (98·0%) of 511 patients had at least one treatment-emergent adverse event."	2.90	Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. ( Balanag, V; Bielskiene, V; Cadena, E; Caoili, J; Cirule, A; Danilovits, M; Davidaviciene, E; Domente, L; Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Lizarbe, V; Patientia, R; Petersen, C; Sanchez, E; Segura, P; Staples, S; Ticona, E; Variava, E; von Groote-Bidlingmaier, F; Wells, C; Yu, C, 2019)
"Reference standards were culture (pulmonary tuberculosis detection); phenotypic DST (pDST), genotypic DST (gDST),composite (pDST and gDST) (drug resistance detection)."	2.82	Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. ( Chaplin, M; Davies, GR; De Vos, M; Pillay, S; Schumacher, SG; Steingart, KR; Theron, G; Warren, R, 2022)
" We also assessed safety and tolerability by monitoring adverse events."	2.80	Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul ( Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F, 2015)
"The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years."	2.71	A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. ( Andries, K; Cambau, E; de Chaffoy, D; Göhlmann, HW; Guillemont, J; Hoffner, S; Huitric, E; Jarlier, V; Lee, E; Lounis, N; Neefs, JM; Timmerman, P; Truffot-Pernot, C; Van Gestel, J; Verhasselt, P; Williams, P; Winkler, H; Zhu, M, 2005)
"After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter."	2.71	[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis]. ( Li, SM; Xing, BC; Zheng, XM, 2004)
"Fifty patients with drug-resistant pulmonary tuberculosis were managed by withdrawing all anti-tuberculosis drugs until the results of a drug sensitivity test were obtained (approximately 3 months), and then a 12-month self-administered regimen with four to six anti-tuberculosis drugs at full daily doses was initiated, based primarily on the sensitivity test and secondarily on the history of previous treatment."	2.70	Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. ( Martínez-Rossier, LA; Pérez-Guzmán, C; Torres-Cruz, A; Vargas, MH; Villarreal-Velarde, H, 2002)
"(1) Most patients with drug-resistant pulmonary tuberculosis were middle-aged or past middle-aged."	2.68	[The present situation, treatment and prognosis of drug-resistant pulmonary tuberculosis. Cooperative Study Unit of Chemotherapy of Tuberculosis of the National Sanitoria in Japan]. ( Katayama, T; Kurashima, A; Mori, M; Nagai, H; Sato, K, 1995)
" New data on optimal drug selection and dosing are emerging with the inclusion of children in clinical trials and ongoing research on age-related pharmacokinetics and pharmacodynamics."	2.66	Tuberculosis treatment in children: The changing landscape. ( Huynh, J; Marais, BJ; Schaaf, HS; Thwaites, G, 2020)
"Isoniazid has been the backbone of tuberculosis chemotherapy for 6 decades."	2.52	Global and Regional Burden of Isoniazid-Resistant Tuberculosis. ( Becerra, MC; Jenkins, HE; Keshavjee, S; Rodriguez, CA; Yuen, CM, 2015)
"To supplement previous state-of-art reviews on anti-tuberculosis treatment and to pave the way forward with reference to the current status, we systematically reviewed published literature on clinical research on tuberculosis (TB) over the past decade in the treatment of drug-susceptible and multidrug-resistant TB (MDR-TB), with a focus on drugs, dosing factors and regimens."	2.52	Clinical research in the treatment of tuberculosis: current status and future prospects. ( Chang, KC; Sotgiu, G; Yew, WW, 2015)
"HIV is the top and tuberculosis is the second leading cause of death from infectious disease worldwide, with an estimated 8."	2.50	Tuberculosis and HIV co-infection in children. ( Chiappini, E; de Martino, M; Galli, L; Thorne, C; Turkova, A; Venturini, E, 2014)
"Drug-resistant tuberculous meningitis is associated with a high mortality."	2.49	Drug-resistant tuberculous meningitis. ( Agrawal, A; Garg, R; Garg, RK; Jain, A; Malhotra, HS, 2013)
" PubMed, Ovid MEDLINE and EMBASE were systematically searched for publications in English to evaluate the evidence about dosing schedules and treatment efficacy."	2.47	Treatment of tuberculosis and optimal dosing schedules. ( Chang, KC; Grosset, J; Leung, CC; Yew, WW, 2011)
"For isoniazid it was 94% and 100% for NRA, 92% and 96% for MODS, 71% and 100% for Genotype MTBDR, and 96% and 100% with the Genotype MTBDRplus, respectively."	2.45	Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. ( Bwanga, F; Haile, M; Hoffner, S; Joloba, ML, 2009)
"Chemotherapy for tuberculosis is indicated in case of disease as well as in latent tuberculosis infection."	2.42	[Tuberculosis-current therapeutic principles]. ( Greinert, U; Zabel, P, 2003)
"Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis."	2.40	[Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997)
"Isoniazid is a first-line pro-drug that requires activation through an enzyme called catalase peroxidase, but is subject to widespread resistance, driven by mutations in katG and inhA genes and other loci with compensatory effects (e."	1.91	Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. ( Ahmad, S; Alam, J; Ali, S; Campino, S; Clark, TG; Khan, AS; Khan, MT; Khan, TA; Khattak, B; Mohammad, N; Napier, G; Phelan, JE; Qasim, M, 2023)
"Four patients (2."	1.91	Evaluation of treatment regimens and long-term clinical outcomes in patients with isoniazid-resistant pulmonary tuberculosis: a 5-year follow-up. ( Aslan, AF; Bağcı, BA; Ortaköylü, MG; Toprak, S, 2023)
" para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells."	1.72	Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS). ( Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022)
"Bedaquiline was approved in 2012 by the US FDA, and listed by WHO as a treatment for multidrug-resistant tuberculosis (MDR-TB) in 2018."	1.72	Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. ( Chen, S; Ding, CZ; Franzblau, SG; Guo, F; Huang, Z; Li, L; Li, Y; Luo, W; Shen, L; Tang, D; Wang, B; Xu, D; Yang, M; Zhu, Y, 2022)
"Multidrug-resistant pulmonary tuberculosis (MDR-TB) is a major health problem worldwide."	1.72	Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. ( Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y, 2022)
"Isoniazid resistance was significantly associated with the Beijing genotype of Lineage 2 (19."	1.72	Association between Mycobacterium tuberculosis genotype and diabetes mellitus/hypertension: a molecular study. ( Chaiprasert, A; Chen, H; Chongsuvivatwong, V; Guo, S; Lei, S; Li, J; Luo, R; McNeil, E; Ou, W; Palittapongarnpim, P; Qin, W; Surachat, K; Zhang, S, 2022)
"Isoniazid displays saturable kinetics at doses >10 mg/kg."	1.72	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. ( Chirehwa, M; Court, R; de Jager, V; de Vries, N; Denti, P; Diacon, A; Dooley, KE; Gausi, K; Gumbo, T; Hafner, R; Harding, J; Ignatius, EH; McIlleron, H; Moran, L; Rosenkranz, SL; Sun, X; Swindells, S; Wiesner, L, 2022)
"Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb."	1.72	An effective nano drug delivery and combination therapy for the treatment of Tuberculosis. ( Amiri, V; Delorme, V; Ebrahimzadeh, N; Kasaeian, A; Maleki, M; Masoumi, M; Pourazar, S; Sadeghinia, M; Sheikhpour, M, 2022)
"Pyrazinamide resistance was found in 6/80 (7."	1.72	Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022)
"Mycobacterium tuberculosis is one of the hardest to treat bacterial pathogens with a high capacity to develop antibiotic resistance by mutations."	1.72	Dynamics of Extensive Drug Resistance Evolution of Mycobacterium tuberculosis in a Single Patient During 9 Years of Disease and Treatment. ( Andersson, DI; Hjort, K; Hoffner, S; Jurén, P; Sandegren, L; Toro, JC, 2022)
"All ciprofloxacin DST results were susceptible by both methods."	1.56	MDR/XDR-TB Colour Test for drug susceptibility testing of Mycobacterium tuberculosis, Northwest Ethiopia. ( Balada-Llasat, JM; Evans, CA; Gelaw, B; Kelley, HV; Shibabaw, A; Tesfaye, E; Tessema, B; Torrelles, JB; Wang, SH, 2020)
"Isoniazid (INH) is a cornerstone of antitubercular therapy."	1.56	Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug. ( Barkan, D; Behr, MA; Chang, YF; McIntosh, F; Meir, M; Meyer, T; Reingewertz, TH; Sullivan, J, 2020)
"Isoniazid data were available from 156 countries or territories for 211,753 patients."	1.56	Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. ( Alikhanova, N; Ama, MCG; Cabibbe, AM; Cirillo, DM; Dean, AS; Falzon, D; Floyd, K; Glaziou, P; Gonzalez-Angulo, LY; Ismail, N; Kamal, SMM; Köser, CU; Skrahina, A; Tahseen, S; Tosas-Auget, O; Zignol, M, 2020)
"Initial Hr caused a large recurrence excess after the 8-month regimen for new cases (rifampicin for two months), but had little impact on rifampicin-throughout regimens: (6 months, new cases; 3."	1.56	The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. ( de Jong, BC; Decroo, T; Gumusboga, M; Hossain, MA; Kya Jai Maug, A; Lynen, L; Mulders, W; Ortuño-Gutiérrez, N; Rieder, HL; Van Deun, A, 2020)
"Isoniazid is an essential drug in the management of tuberculosis but there is a high degree of variation in the Indian population's capacity to acetylate or inactivate isoniazid to the inactive metabolite acetyl isoniazid, and they can be distinctly characterized phenotypically as being either slow or rapid inactivators (the concentration of the enzyme being higher in rapid inactivators)."	1.56	A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India. ( Darole, P; Munshi, R; Panchal, F; Shetty, P; Sundar, U, 2020)
"Isoniazid resistance was observed in 40% (23/58 tested) and rifampin resistance in 19."	1.51	High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study. ( Bamfo, TD; Bouton, TC; Carter, J; Forson, A; Jacobson, K; Jenkins, H; Kudzawu, S; Kwara, A; Zigah, F, 2019)
"Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria."	1.51	[Tuberculosis]. ( Heyckendorf, J; Kalsdorf, B; Lange, C; Maurer, FP, 2019)
"Thus, the sensitivity and specificity were observed to be 100% for all three tested drugs when compared with indirect DST."	1.51	Direct drug susceptibility testing of Mycobacterium tuberculosis using the proportional method: A multicenter study. ( Allahyar Torkaman, MR; Amini, S; Hamzehloo, G; Hoffner, S; Mir, R; Mohsenpoor, M; Nasiri, MJ; Salehi, M; Sami Kashkooli, G; Shahraki, MS; Soleimanpour, S, 2019)
" Four concentrations of fresh pomegranate juice (FPJ) (5%, 10%, 15%, and 20%) were evaluated in combination with R and INH at a dose range of (1."	1.51	Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates. ( AlMatar, M; Eker, E; Kafkas, E; Kayar, B; Köksal, F; Var, I; Zarifikhosroshahi, M, 2019)
" Stochastic PK/pharmacodynamic (PD) simulations were carried out to evaluate current regimen combinations and dosing guidelines in distinct patient strata."	1.51	Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. ( Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M, 2019)
"Isoniazid (INH) is a key element of the first line anti tuberculosis treatment regimen."	1.51	Use of nanotechnology for infectious disease diagnostics: application in drug resistant tuberculosis. ( Adikaram, CP; De Silva, KMN; Karunaratne, RE; Perera, J; Wijenayaka, LA; Wijesundera, SS, 2019)
"Pulmonary tuberculosis was bacteriologically confirmed in 4 057 subjects."	1.51	Tuberculosis in Poland in 2017 ( Korzeniewska- Koseła, M, 2019)
" Monotherapy with an orally bioavailable MptpB inhibitor reduces infection burden in acute and chronic guinea pig models and improves the overall pathology."	1.48	Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo. ( Cavet, JS; Chakraborty, A; Fernandez, P; Gutierrez, MG; Kreiswith, BN; Kurepina, N; Naranjo, Y; Park, S; Perlin, DS; Pons, M; Saville, C; Schnettger, LS; Silva, APG; Tabernero, L; Thomas, EJ; Vickers, CF, 2018)
"Treatment of isoniazid, rifampicin, pyrazinamide with the diagnosis of epituberculosis was started by taking a sample of gastric aspirate culture sample."	1.48	[Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case]. ( Acar, EM; Bayramoğlu, Z; Çalışkan, E; Erköse, G; Hançerli Törün, S; Kılıçaslan, Z; Şatana, D; Somer, A, 2018)
"Drug resistant tuberculosis is increasing world-wide."	1.48	Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. ( Kirschner, DE; Linderman, JJ; Pienaar, E, 2018)
"In new pulmonary tuberculosis patients, rapid spread of MDR-TB and XDR-TB challenging the effectiveness of national TB control programs especially in many low-income countries."	1.48	Drug resistance pattern in Mycobacterium tuberculosis to the first line drugs of pulmonary tuberculosis patients at Hazara Region, Pakistan. ( Ahmad, M; Ahmad, W; Akbar, HS; Akbar, MT; Jan, F; Khalid, A; Sadia, S; Wali, S, 2018)
"Ethionamide is an important contributor to MDR-TB treatment regimens, at Sensititre MIC <2."	1.48	Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. ( Bendet, P; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S, 2018)
" Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis."	1.46	Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017)
" As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan."	1.46	Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit. ( Chen, J; Chiang, CY; Innes, AL; Li, L; Xu, L, 2017)
" Further, this PMAA/INH/RMP nanogel exhibited lower cytotoxicity than did INH or RMP alone, suggesting that this PMAA/INH/RMP nanogel could be a more useful dosage form than separate doses of INH and RMP for intestinal MTB."	1.43	Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis. ( Chen, L; Chen, T; Chen, X; Guo, H; Guo, L; Li, H; Li, Q; Li, Z; Wu, T; Yu, L; Zhao, M; Zhong, Q; Zhou, L, 2016)
"Contact tracing of a case of pulmonary tuberculosis was performed in a Bolivian patient."	1.43	Outbreak of isoniazid-resistant tuberculosis in an immigrant community in Spain. ( Andrés García, I; Eiros Bouza, JM; Fernández Arribas, S; Fernández Espinilla, V; Hernán García, C; Moreno Cea, L; Rubio, V; Ruiz Lopez Del Prado, G; Vesenbeckh, S, 2016)
"To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients."	1.42	High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015)
"Tetrandrine is a natural chemical product purified from fourstamen stephania root which recently has been shown to act similarly as synthesized drug efflux pump inhibitor verapamil."	1.42	Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates. ( Ji, Z; Li, L; Xu, K; Yan, J; Zhang, Z, 2015)
"The MDR tuberculosis was much more prevalent among those who had previous history of treatment."	1.42	Epidemiological Characterization of Drug Resistance among Mycobacterium tuberculosis Isolated from Patients in Northeast of Iran during 2012-2013. ( Ayati Fard, SF; Bahrami Taghanaki, HR; Ghazvini, K; Salehi, M; Shakiba, A; Tavanaee Sani, A, 2015)
"Ethionamide (ETH) is an antibiotic used for the treatment of multidrug-resistant (MDR) tuberculosis (TB) (MDR-TB), and its use may be limited with the emergence of resistance in the Mycobacterium tuberculosis population."	1.42	Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates. ( Ferro, BE; Mejia, GI; Realpe, T; Robledo, J; Rozo, JC; Rueda, J; Zapata, E, 2015)
" The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80."	1.40	Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent. ( Ahn, S; Choi, I; Jang, J; Kang, H; Kang, S; Kim, HJ; Kim, J; Kim, RY; Kim, YM; Ko, Y; Lee, S; Nam, J; Nam, K; No, Z; Park, S; Pethe, K; Seo, JJ; Seo, M; Seo, MJ, 2014)
"Worldwide highest number of new pulmonary tuberculosis (PTB) cases, was reported from India in 2012."	1.40	Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India. ( Bhattacharya, B; Chakraborty, U; Das, A; Das, S; Dey, SK; Goswami, A; Mahapatra, S; Mahapatra, T; Mukherjee, T; Pal, NK; Ray, S, 2014)
"tuberculosis strain in a patient with mixed infection."	1.39	Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection. ( Bremang, S; Casey, R; Connell, D; Evans, JT; Hawkey, PM; Hingley-Wilson, SM; Jepson, A; Kon, OM; Lalvani, A; Philip, S; Smith, GE, 2013)
"Sensitivity and specificity were 98% and 99% respectively for detection of RIF resistance; 92% and 99% respectively for detection of INH resistance; 97% and 100% respectively for detection of MDR-TB."	1.39	Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. ( Arora, SK; Hanif, M; Kumar, A; Myneedu, VP; Paramasivan, CN; Raizada, N; Sachdeva, KS; Sharma, R; Sharma, SK; Singh, BK; Sinha, S; Soneja, M; Sreenivas, V; Thakur, R; Vollepore, B; Yadav, RN, 2013)
"Tuberculosis is still a global health problem all over the world despite its mortality has been decreased with effective treatment regimens."	1.39	Unfinished battle with childhood tuberculosis: is it curable with less drugs and shorter duration? ( Cinel, G; Çobanoğlu, N; Doğru, D; Göçmen, A; Kiper, N; Köse, M; Koyun, M; Özçelik, U; Pekcan, S; Tana Aslan, A; Yalçın, E, 2013)
"Tuberculous meningitis is the most severe form of tuberculosis and causes substantial morbidity and mortality in adults and children."	1.38	Description of primary multidrug-resistant tuberculous meningitis in an Italian child. ( Cavalcanti, P; Giraldi, C; Ledonne, R; Mauro, MV; Sperlì, D, 2012)
" In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations."	1.38	Therapeutic drug monitoring in the treatment of tuberculosis patients. ( Aarnoutse, R; Boeree, M; Ijdema, D; Magis-Escurra, C; van den Boogaard, J, 2012)
"The sensitivity and specificity were 75-100% and 31."	1.38	Training laboratory technicians from the Ethiopian periphery in the MODS technique enables rapid and low-cost diagnosis of Mycobacterium tuberculosis infection. ( Block, C; Caviedes, L; Elinav, H; Kalter, HD; Lemma, E; Maayan, S; Moulton, LH; Rajs, A, 2012)
" Noncompliance treatment, simulated by a reduced duration and dosing frequency, resulted in a relapse of infection."	1.38	Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis. ( Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; den Bakker, MA; ten Kate, MT; van Soolingen, D; Verbrugh, HA, 2012)
"Isoniazid resistance was detected in two tuberculosis patients, while rifampin resistance was detected in one tuberculosis patient; there was another patient whose Mycobacterium tuberculosis isolate was resistant to both isoniazid and rifampin (belongs to multidrug resistance tuberculosis)."	1.38	Gene chip array for differentiation of mycobacterial species and detection of drug resistance. ( Liu, XQ; Shi, XC; Xie, XL; Xu, YC; Zhao, ZX, 2012)
"Isoniazid (INH) is a central component of drug regimens used worldwide to treat tuberculosis."	1.37	Prevalence of mutations at codon 463 of katG gene in MDR and XDR clinical isolates of Mycobacterium tuberculosis in Belarus and application of the method in rapid diagnosis. ( Arjomandzadegan, M; Farazi, AA; Ghaznavi-Rad, E; Owlia, P; Ranjbar, R; Sadrnia, M; Sofian, M; Surkova, LK; Titov, LP, 2011)
"Isolated INH-resistant intracranial tuberculoma is rare in adults."	1.37	Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. ( Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK, 2011)
" One of the major mechanisms proposed to lead to the emergence of drug resistance is pharmacokinetic mismatch."	1.37	Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. ( Gumbo, T; Leff, R; Meek, C; Sherman, C; Srivastava, S, 2011)
" We also explored the effect of pharmacokinetic variability on MDR-tuberculosis emergence using computer-aided clinical trial simulations of 10 000 Cape Town, South Africa, tuberculosis patients."	1.37	Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. ( Gumbo, T; Leff, R; Meek, C; Pasipanodya, JG; Srivastava, S, 2011)
" Population pharmacokinetic parameters and their variability encountered in tuberculosis patients were utilized in Monte Carlo simulations to determine the probability that particular daily doses of the drugs would achieve or exceed the EC(90) in the epithelial lining fluid of 10,000 tuberculosis patients."	1.36	New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ( Gumbo, T, 2010)
"Pyrazinamide (PZA) is an important first-line antituberculous drug, which is applied together with INH, RMP, EMB and SM."	1.36	[Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland]. ( Augustynowicz-Kopeć, E; Napiórkowska, A; Zwolska, Z, 2010)
"Of 250 cases started on Category II retreatment, 209 were relapse cases; of these, 18 were INH-resistant RMP-susceptible, 18 were INH+RMP-resistant and nine were culture-negative."	1.36	Risk of relapse and failure after retreatment with the Category II regimen in Nepal. ( Maharjan, B; Shrestha, B; Yoshiyama, T, 2010)
"Tuberculosis is a major cause of mortality among patients with HIV and poses a risk throughout the course of HIV disease, even after successful initiation of antiretroviral therapy (ART)."	1.35	Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. ( Getahun, H; Havlir, DV; Nunn, P; Sanne, I, 2008)
"Resectional lung surgery combined with isoniazid- and rifampin-based anti-tuberculous chemotherapy can be an effective treatment strategy for patients with well-localized, cavitary pulmonary MDR-TB and XDR-TB."	1.35	Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. ( Cho, JS; Kang, H; Kim, JH; Park, SK; Smego, RA, 2009)
"Patients with active pulmonary tuberculosis (TB) infect 10-15 other persons per year, making diagnosing active TB essential to both curing the patient and preventing new infections."	1.35	The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis. ( Brady, MF; Coronel, J; Gilman, RH; Moore, DA, 2008)
"Treatment with isoniazid plus rifampin was the most effective but would cost more than $1 million per reactivation case prevented."	1.35	Latent tuberculosis infection in children: a call for revised treatment guidelines. ( Christenson, JC; Downs, SM; Finnell, SM, 2009)
" This study was aimed to investigate the in vitro effect of linezolid alone and in combination with isoniazid and rifampicin against 10 multidrug resistant M."	1.35	[Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates]. ( Bilgin, K; Coban, AY; Durupinar, B; Uzun, M, 2009)
"Ethionamide (ETH) is a structural analogue of isoniazid (INH)."	1.35	Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. ( Brittle, W; Donald, PR; Hesseling, AC; Jordaan, AM; Marais, BJ; Schaaf, HS; van Helden, PD; Venter, A; Victor, TC, 2009)
"Isoniazid preventive treatment (IPT) is particularly beneficial in the case of children who are infected with the human immunodeficiency virus (HIV)."	1.34	Chapter 4: childhood contact screening and management. ( , 2007)
" The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time."	1.34	Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences. ( Barrera, L; de Kantor, IN, 2007)
"Tubercular tenosynovitis is now rare, which can delay diagnosis of this disease."	1.33	Tenosynovitis of the wrist due to resistant Mycobacterium tuberculosis in a heart transplant patient. ( Arvieux, C; Cormier, M; Guggenbuhl, P; Jolivet-Gougeon, A; Le Meur, A, 2005)
"Thirty six children were treated for MDR tuberculosis, of whom four died."	1.32	Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. ( Donald, PR; Schaaf, HS; Shean, K, 2003)
"Reports of MDR TB meningitis (MDR-TBM), however, are limited to case reports and a single case series."	1.32	Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. ( Allen, J; Bhagwan, B; Bhigjee, AI; Moodley, AA; Mthiyane, T; Padayatchi, N; Patel, VB, 2004)
"Tuberculosis is a major cause of childhood morbidity and mortality in high-burden settings, particularly in the third-world settings."	1.32	Childhood turberculosis: reflections from the front line. ( Marais, BJ, 2004)
"To determine the frequency of TB recurrence among MDR (multidrug-resistant) patients who achieved treatment 'success' on standard short-course chemotherapy."	1.31	Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. ( Danilova, ID; Espinal, M; Grzemska, M; Migliori, GB; Punga, VV; Raviglione, MC, 2002)
"A total of 1472 pulmonary tuberculosis patients who had taken anti-tuberculosis treatment were evaluated retrospectively with respect to their drug resistance pattern by sputum culture for acid-fast bacilli (AFB) and sensitivity testing with isoniazid, rifampicin, streptomycin and ethambutol (E)."	1.31	Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. ( Agarwal, SK; Shah, AR; Shah, KV, 2002)
"Two patients with multidrug-resistant pulmonary tuberculosis were surgically treated after 3 and 7 years of unsuccessful chemotherapy."	1.30	[Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports]. ( Kuś, J; Michałowska-Mitczuk, D, 1997)
"Isoniazid resistance was most prevalent, being found in 72% of isolates, followed by streptomycin resistance in 45%."	1.30	Drug-resistant tuberculosis in Singapore, 1995 to 1996. ( Boudville, IC; Snodgrass, I; Wong, SY, 1997)
"In this study, multidrug-resistant pulmonary tuberculosis responded relatively well to carefully selected regimens."	1.30	Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. ( Kim, CT; Park, SK; Song, SD, 1998)
"785 patients with pulmonary tuberculosis (both old = 525/785 and new = 260/785 cases) referred to our center were evaluated with respect to their drug resistance patterns."	1.29	High initial and acquired drug resistance in pulmonary tuberculosis in Turkey. ( Karagöz, T; Kizkin, O; Partal, M; Sadoğlu, T; Tahaoğlu, K; Tor, M, 1994)
"Culture positive pulmonary tuberculosis occurred in 292 patients."	1.29	Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992. ( al Jarad, N; Empey, DW; Gaya, H; Parastatides, S; Paul, EA; Rudd, RM; Sheldon, CD, 1994)
"Sputum samples from pulmonary tuberculosis patients attending a hospital for chest diseases and tuberculosis at Jaipur, India were directly subjected to sensitivity tests to detect drug resistance to streptomycin (S), isoniazid (I), rifampicin (R) and ethambutol (Emb) by slide culture technique."	1.29	Prevalence of initial drug resistance in tuberculosis patients attending a chest hospital. ( Gupta, PR; Gupta, RB; Sharma, TN; Singhal, B, 1993)
"133 homeless subjects with pulmonary tuberculosis were examined microbiologically in Moscow Tuberculosis Hospital N 7 in 1993-1994."	1.29	[Biological characteristics of mycobacterial agent in homeless patients with pulmonary tuberculosis]. ( Batyrov, FA; Dorozhkova, IR; Kornilova, ZKh, 1996)
"There are few reports of children with AIDS and TB."	1.29	Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. ( Birnbaum, J; Chan, SP; Rao, M; Steiner, P, 1996)
"Nosocomial transmission among 7 AIDS patients admitted into the same ward between June and December/94 was supported by temporal clustering of cases, matching drug susceptibility, and identical IS6110 fingerprints."	1.29	Hospital transmission of multidrug-resistant Mycobacterium tuberculosis in Rosario, Argentina. ( Aita, J; Barrera, L; Biglione, J; Largacha, C; Lopez, B; Rajmil, JC; Reniero, A; Ritacco, V; Weisburd, G, 1996)
"Treatment with isoniazid and a fluoroquinolone antibiotic was also independently associated with longer survival."	1.29	A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. ( Alland, D; Brudney, K; Crawford, JT; Frieden, TR; Fujiwara, PI; Hewlett, D; Kreisworth, BN; Maw, KL; Nivin, B; Sharp, V; Sherman, LF, 1996)
"We describe a patient with acute lymphocytic leukemia and multidrug-resistant tuberculosis of the brain and spinal cord."	1.29	Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. ( Atweh, S; Hachem, R; Leeds, N; Raad, I; Salem, Z; Sawaya, R, 1996)
"The prophylaxis of tuberculosis is cost-effective in that it prevents hospitalizations and eliminates the need for multidrug treatment of active disease."	1.29	Prophylaxis of mycobacterial infections in immunocompromised patients. ( Fisher, MA; Krance, MB, 1996)

Research

Studies (1,142)

Authors

Clinical Trials (37)

Trial Overview

Trial Outcomes

Mean (Time Averaged) Area Under The Curve (AUC) Of Change From Baseline In Time To Detection (TTD) To Month 6 Using MGIT

Timeframe	Studies, this research(%)	All Research%
pre-1990	29 (2.54)	18.7374
1990's	108 (9.46)	18.2507
2000's	238 (20.84)	29.6817
2010's	566 (49.56)	24.3611
2020's	201 (17.60)	2.80

Authors	Studies
Andries, K	2
Verhasselt, P	1
Guillemont, J	1
Göhlmann, HW	1
Neefs, JM	1
Winkler, H	1
Van Gestel, J	1
Timmerman, P	1
Zhu, M	1
Lee, E	1
Williams, P	1
de Chaffoy, D	1
Huitric, E	1
Hoffner, S	16
Cambau, E	2
Truffot-Pernot, C	4
Lounis, N	1
Jarlier, V	3
Gegia, M	1
Mdivani, N	1
Mendes, RE	1
Li, H	5
Akhalaia, M	1
Han, J	2
Khechinashvili, G	2
Tang, YW	2
Luo, T	2
Zhao, M	3
Li, X	3
Xu, P	4
Gui, X	1
Pickerill, S	1
DeRiemer, K	2
Mei, J	2
Gao, Q	5
Krátký, M	4
Vinšová, J	5
Buchta, V	1
Horvati, K	3
Bösze, S	4
Stolaříková, J	5
Vavříková, E	1
Polanc, S	1
Kočevar, M	1
Vávrová, K	1
Li, YB	1
Xie, YY	1
Du, NN	1
Lu, Y	8
Xu, HZ	1
Wang, B	12
Yu, Y	1
Liu, YX	1
Song, DQ	1
Chen, RX	1
Ahsan, MJ	1
Samy, JG	1
Jain, CB	1
Dutt, KR	1
Khalilullah, H	1
Nomani, MS	1
Sureram, S	1
Senadeera, SP	1
Hongmanee, P	1
Mahidol, C	1
Ruchirawat, S	1
Kittakoop, P	1
Claes, P	1
Cappoen, D	1
Uythethofken, C	1
Jacobs, J	1
Mertens, B	1
Mathys, V	1
Verschaeve, L	1
Huygen, K	2
De Kimpe, N	1
Kang, S	1
Kim, RY	1
Seo, MJ	1
Lee, S	1
Kim, YM	1
Seo, M	1
Seo, JJ	1
Ko, Y	1
Choi, I	1
Jang, J	1
Nam, J	1
Park, S	3
Kang, H	3
Kim, HJ	4
Kim, J	4
Ahn, S	1
Pethe, K	1
Nam, K	1
No, Z	1
Poce, G	1
Cocozza, M	1
Consalvi, S	1
Biava, M	1
Baranyai, Z	2
Szabó, I	1
Paraskevopoulos, G	2
Pieroni, M	1
Wan, B	2
Zuliani, V	1
Franzblau, SG	4
Costantino, G	1
Rivara, M	1
Szabó, N	1
Senoner, Z	1
Dávid, S	2
Mahajan, NS	1
Dhawale, SC	1
Zhang, T	3
Shen, W	1
Liu, M	6
Zhang, R	1
Wang, M	1
Li, L	9
Guo, H	4
Ng, PS	1
Manjunatha, UH	1
Rao, SP	1
Camacho, LR	1
Ma, NL	1
Herve, M	1
Noble, CG	1
Goh, A	1
Peukert, S	1
Diagana, TT	1
Smith, PW	1
Kondreddi, RR	1
Choi, J	1
Park, SJ	1
Jee, JG	1
Santivañez-Veliz, M	1
Pérez-Silanes, S	1
Torres, E	1
Moreno-Viguri, E	1
Stec, J	1
Onajole, OK	1
Lun, S	2
Merenbloom, B	1
Vistoli, G	1
Bishai, WR	4
Kozikowski, AP	1
Monteiro, S	1
Vosátka, R	1
Navrátilová, L	1
Trejtnar, F	1
Hu, YQ	1
Zhang, S	4
Zhao, F	1
Gao, C	1
Feng, LS	1
Lv, ZS	1
Xu, Z	3
Wu, X	4
Gomes, MN	1
Braga, RC	1
Grzelak, EM	1
Neves, BJ	1
Muratov, E	1
Ma, R	1
Klein, LL	1
Cho, S	2
Oliveira, GR	1
Andrade, CH	1
Vickers, CF	1
Silva, APG	1
Chakraborty, A	1
Fernandez, P	1
Kurepina, N	3
Saville, C	1
Naranjo, Y	1
Pons, M	1
Schnettger, LS	1
Gutierrez, MG	1
Kreiswith, BN	1
Perlin, DS	1
Thomas, EJ	1
Cavet, JS	1
Tabernero, L	1
Makane, VB	1
Krishna, VS	1
Krishna, EV	1
Shukla, M	1
Mahizhaveni, B	1
Misra, S	1
Chopra, S	2
Sriram, D	1
Dusthackeer, VNA	1
Rode, HB	1
Patel, H	1
Jadhav, H	1
Ansari, I	1
Pawara, R	1
Surana, S	1
Zhao, W	2
Liu, Y	6
Fu, L	6
Sheng, L	2
Zhao, H	2
Zhang, D	2
Wang, A	1
Ma, C	2
Chai, Y	1
Liu, X	3
Lv, K	1
Jia, X	1
Li, G	4
Lu, H	1
Li, Y	10
Zhang, B	2
Huang, H	3
Li, D	2
Liu, C	2
Jiang, X	4
Lin, Y	2
Zhang, J	5
You, X	1
Jiang, W	3
Chen, M	1
Xu, Y	2
Si, S	1
Cavalier, JF	1
Spilling, CD	1
Durand, T	1
Camoin, L	1
Canaan, S	1
Zloh, M	1
Gupta, M	2
Parish, T	1
Brucoli, F	1
Liu, J	3
Dai, H	1
Liu, H	3
Tian, Z	1
Zhang, Y	8
Qin, R	1
Wang, P	1
Batt, SM	1
Besra, GS	1
Wu, C	1
Wang, Y	10
Hegde, PV	1
Howe, MD	1
Zimmerman, MD	2
Boshoff, HIM	1
Sharma, S	3
Remache, B	1
Jia, Z	1
Pan, Y	3
Baughn, AD	1
Dartois, V	3
Aldrich, CC	1
Kumar Sahoo, S	1
Maddipatla, S	1
Nageswara Rao Gajula, S	1
Naiyaz Ahmad, M	1
Kaul, G	1
Nanduri, S	1
Sonti, R	1
Dasgupta, A	1
Madhavi Yaddanapudi, V	1
Huang, Z	2
Luo, W	2
Xu, D	2
Guo, F	1
Yang, M	2
Zhu, Y	5
Shen, L	3
Chen, S	3
Tang, D	1
Ding, CZ	2
Tao, X	1
Bin, W	1
Hu, Y	4
Jiang, N	1
Wei, Y	1
Wei, X	1
Merker, M	2
Egbe, NF	1
Ngangue, YR	1
Vuchas, C	1
Kohl, TA	1
Dreyer, V	1
Kuaban, C	4
Noeske, J	2
Niemann, S	8
Sander, MS	1
Feng, G	1
Han, W	1
Shi, J	4
Xia, R	1
Xu, J	4
Diriba, G	5
Tola, HH	2
Alemu, A	3
Yenew, B	4
Gamtesa, DF	1
Kebede, A	4
Penn-Nicholson, A	1
Georghiou, SB	5
Ciobanu, N	4
Kazi, M	1
Bhalla, M	5
David, A	2
Conradie, F	2
Ruhwald, M	2
Crudu, V	7
Rodrigues, C	6
Myneedu, VP	6
Scott, L	3
Denkinger, CM	5
Schumacher, SG	5
Amer, S	1
El Hefnawy, A	1
Baz, A	1
Okasha, H	1
Thwe, EP	1
Namwat, W	1
Pinlaor, P	1
Rueangsak, K	1
Sangka, A	1
Alffenaar, JC	3
Marais, BJ	7
Thomas, TA	2
Sağıroğlu, P	1
Atalay, MA	1
Khurana, P	1
Saigal, K	1
Ghosh, A	2
Gliddon, HD	1
Frampton, D	1
Munsamy, V	1
Heaney, J	1
Pataillot-Meakin, T	1
Nastouli, E	1
Pym, AS	4
Steyn, AJC	1
Pillay, D	1
McKendry, RA	1
Nie, Q	1
Tao, L	1
Chen, N	1
Chen, H	3
Zhou, Y	5
Tang, Q	1
Wang, X	6
Huang, C	1
Yang, C	1
Habiburrahman, M	1
Ariq, H	1
Handayani, RRD	1
Kendall, EA	1
Hussain, H	2
Kunkel, A	1
Kubiak, RW	1
Trajman, A	1
Menzies, R	1
Drain, PK	1
Posey, DL	1
Yang, Q	1
Weinberg, MS	1
Maloney, SA	1
Lambert, LA	1
Ortega, LS	1
Marano, N	1
Cetron, MS	1
Phares, CR	1
Ng, KKM	1
Yip, PCW	1
Leung, PKL	1
Karmakar, M	1
Ragonnet, R	1
Ascher, DB	2
Trauer, JM	1
Denholm, JT	1
Khan, FU	2
Rehman, AU	1
Hayat, K	1
Khan, A	1
Ahmad, N	2
Chang, J	2
Malik, UR	1
Fang, Y	1
Anthwal, D	3
Jamwal, S	1
Gupta, RK	3
Singhal, R	4
Verma, AK	2
Sarin, R	5
Choudhary, S	2
Tyagi, JS	3
Haldar, S	3
Espinosa-Pereiro, J	1
Sánchez-Montalvá, A	1
Aznar, ML	1
Espiau, M	1
Benaissa, E	1
Benlahlou, Y	1
Bssaibis, F	1
Maleb, A	1
Elouennass, M	1
Soltobekova, N	1
Kozukeev, T	1
Yiehdego, G	1
Labib, F	1
Hovhannesyan, A	1
Rossi, R	1
Tan, G	1
Sha, W	2
Yang, J	3
Guo, Y	1
Shen, X	2
Wu, Z	4
Shen, H	1
Yu, F	1
Tiberi, S	4
Utjesanovic, N	1
Galvin, J	1
Centis, R	3
D'Ambrosio, L	3
van den Boom, M	1
Zumla, A	7
Migliori, GB	12
Nachappa, SA	2
Neelambike, SM	2
Ramachandra, NB	2
Bakhtiyariniya, P	1
Khosravi, AD	3
Hashemzadeh, M	2
Savari, M	2
Aono, A	6
Murase, Y	1
Minegishi, M	1
Ohtawa, S	1
Yano, M	1
Chikamatsu, K	3
Shimomura, Y	1
Hosoya, M	1
Igarashi, Y	2
Morishige, Y	1
Yamada, H	4
Takaki, A	2
Togashi, K	1
Hiura, M	1
Mitarai, S	6
Vogensen, VB	1
Anthony, RM	3
Kerstjens, HAM	1
de Steenwinkel, JEM	1
Akkerman, OW	3
Park, M	1
Lalvani, A	2
Satta, G	2
Kon, OM	3
Mujuni, D	1
Kasemire, DL	1
Ibanda, I	1
Kabugo, J	1
Nsawotebba, A	1
Phelan, JE	5
Majwala, RK	2
Tugumisirize, D	1
Nyombi, A	2
Orena, B	1
Turyahabwe, I	1
Byabajungu, H	1
Nadunga, D	1
Musisi, K	3
Joloba, ML	4
Ssengooba, W	4
Shanmugam, SK	1
Kumar, N	4
Sembulingam, T	1
Ramalingam, SB	1
Selvaraj, A	1
Rajendhiran, U	1
Solaiyappan, S	1
Tripathy, SP	2
Natrajan, M	1
Chandrasekaran, P	2
Swaminathan, S	3
Parkhill, J	1
Peacock, SJ	1
Ranganathan, UDK	1
Kreutzfeldt, KM	1
Jansen, RS	1
Hartman, TE	1
Gouzy, A	1
Wang, R	1
Krieger, IV	1
Gengenbacher, M	1
Sarathy, JP	1
Xie, M	1
Sacchettini, JC	4
Rhee, KY	2
Schnappinger, D	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-center, Randomized, Positive-controlled Phase 2 Clinical Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of WX-081 in Participants With Drug-naive&Susceptible or Drug-Resistant Pulmonary Tuberculosis[NCT04608955]	Phase 2	99 participants (Actual)	Interventional	2020-10-16	Completed
Multicentre Clinical Trial to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection[NCT03728725]		710 participants (Actual)	Observational	2019-07-11	Completed
Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963]		3,356 participants (Actual)	Observational	2017-05-04	Completed
Epidemiology of Multidrug-Resistant Tuberculosis in Peru[NCT00676754]		18,544 participants (Actual)	Observational	2009-09-30	Active, not recruiting
Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) Study[NCT04923958]		6,050 participants (Anticipated)	Interventional	2021-04-14	Recruiting
Feasibility and Accuracy of a Novel Xpert Cartridge for Rapid Molecular Detection of Drug Resistant Mycobacterium Tuberculosis in Sputum[NCT02251327]		401 participants (Actual)	Observational	2014-06-04	Completed
A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis[NCT00933790]	Phase 3	331 participants (Actual)	Interventional	2009-09-14	Completed
Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial[NCT01994460]	Phase 2	429 participants (Anticipated)	Interventional	2014-01-31	Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture[NCT01424670]	Phase 3	511 participants (Actual)	Interventional	2011-09-02	Completed
Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery[NCT00816426]	Phase 1	19 participants (Actual)	Interventional	2008-12-29	Completed
A Natural History Study of Multidrug-Resistant Tuberculosis Strains and Host Susceptibility Genes in Korean Patients With Pulmonary Tuberculosis[NCT00341601]		777 participants (Actual)	Observational	2005-01-03	Completed
An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201]	Phase 3	402 participants (Actual)	Interventional	2019-08-22	Active, not recruiting
Artificial Neural Network as Diagnostic Tools For Rifampicin-Resistant Tuberculosis In Indonesia: A Predictive Model Study and Economic Evaluation[NCT04208789]		524 participants (Actual)	Observational	2020-06-15	Completed
A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi D[NCT01498419]	Phase 2	207 participants (Actual)	Interventional	2012-03-31	Completed
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469]		286 participants (Anticipated)	Interventional	2020-03-01	Not yet recruiting
Performance of a Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium Tuberculosis and Non-tuberculous Mycobacterium Species in Smear-positive Pulmonary Clinical Specimens[NCT03794284]		46 participants (Actual)	Observational	2019-02-28	Completed
Global Consortium for Drug-resistant Tuberculosis Diagnostics[NCT02170441]		1,128 participants (Actual)	Observational	2012-04-30	Completed
A Pilot Study to Evaluate Video Observed Treatment Among Tuberculosis Patients From Lambaréné Using an Instant Messenger Application[NCT05865626]		30 participants (Actual)	Interventional	2018-10-10	Completed
Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis[NCT02776150]		3,100 participants (Anticipated)	Observational	2016-05-31	Not yet recruiting
A Natural History Study of Tuberculosis in China; Correlates of a Successful Response to Treatment[NCT01071603]		199 participants (Actual)	Observational	2010-02-02	Completed
Feasibility, Accuracy, and Effect of Point-of-care Xpert MTB/RIF Ultra and Xpert MTB/RIF Ultra Testing in Patients Suspected of Having TB: a Randomised Controlled Trial[NCT03356925]		1,549 participants (Actual)	Interventional	2018-02-06	Completed
Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia[NCT02729532]		776 participants (Actual)	Observational	2016-06-22	Completed
Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056]		360 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610]		630 participants (Anticipated)	Observational	2013-11-30	Recruiting
Novel TB Prevention Regimens for HIV-Infected Adults[NCT00057122]	Phase 3	1,148 participants (Actual)	Interventional	2002-09-30	Completed
Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers[NCT02771249]	Phase 1	37 participants (Actual)	Interventional	2016-06-03	Completed
Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention: the 3HP Options Implementation Trial[NCT03934931]		1,656 participants (Actual)	Interventional	2020-07-13	Active, not recruiting
A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals[NCT02980016]	Phase 3	4,027 participants (Actual)	Interventional	2016-11-30	Completed
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299]	Phase 4	302 participants (Actual)	Interventional	2017-04-07	Completed
Primary Prophylaxis for Prevention of TB in Prison's Populations[NCT03028129]	Phase 4	467 participants (Actual)	Interventional	2017-09-04	Terminated (stopped due to Interim analysis showed efficacy less than 2.5%.)
A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198]	Phase 3	436 participants (Anticipated)	Interventional	2021-12-10	Recruiting
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811]		625 participants (Anticipated)	Observational	2020-01-30	Recruiting
A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817]	Phase 3	520 participants (Actual)	Interventional	2017-05-25	Active, not recruiting
A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786]	Phase 3	640 participants (Anticipated)	Interventional	2018-02-08	Recruiting
A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678]	Phase 2	40 participants (Anticipated)	Interventional	2021-12-07	Recruiting
TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789]		555 participants (Actual)	Interventional	2020-11-17	Active, not recruiting
Nine Months' Short Course Regimen Protocol for the Treatment of Multidrug Resistance-tuberculosis (MDR-TB) Patients in Gabon[NCT03057756]		23 participants (Anticipated)	Observational [Patient Registry]	2015-09-11	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The value for TTD was defined (in days) as the time interval from inoculation until a MGIT machine detects a positive signal for a sputum culture. The AUC of the change from Baseline for TTD in days (from Baseline to Month 6) summarizes the overall participant response for the treatment period. The change from Baseline in original time to detection of MGIT positive signal, in days, up to 6 months was performed using AUC in MGIT. The Baseline was defined as the average of Day -1 and Day 1 values if cultures on both days were positive; if only 1 culture was positive, the value for TTD for the positive culture was used as the Baseline.~The TTD is Time to Detection measured by day, so the unit of AUC of change from baseline in TTD is day*day. Since Mean AUC is reported, which is actually Time Averaged AUC, the AUC was divided by the duration of the observation, and thus the unit of the Mean AUC is day." (NCT01424670)
Timeframe: Baseline, up to Month 6

Number of Participants Who Developed Resistance To Delamanid

Intervention	days (Mean)
Delamanid + OBR	21.9
Placebo + OBR	23.3

Acquired resistance was defined as a post-baseline resistant result at any time point after a Baseline susceptible result. The overall resistance to delamanid during the trial was assessed. (NCT01424670)
Timeframe: Up to Month 30

Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) System

Intervention	participants (Number)
Delamanid + OBR	3
Placebo + OBR	0

SCC at 6 months was determined by the observation of a sputum specimen negative for growth of mycobacterium tuberculosis (MTB) using the MGIT culture system, followed by at least 1 confirmatory negative sputum culture at least 25 days after the first negative and not followed by a confirmed positive (defined as at least 2 observed positive results, not taking into account indeterminate, missing, or contaminated results). 2 specimens were collected at each visit and an algorithm in the statistical analysis plan (SAP) was used to define a single representative result. Time to SCC was then defined as the interval between the date of first dose of IMP and the date of first of 2 consecutive negative single representative time points that were at least 25 days apart. The median time in days to SCC up to Month 6 is presented. (NCT01424670)
Timeframe: Month 6

Mean Change From Baseline In TTD Using The MGIT System

Intervention	Days (Median)
Delamanid + OBR	51
Placebo + OBR	57

The value for TTD was defined (in days) as the time interval from inoculation until a MGIT machine detects a positive signal for a sputum culture during the routine 42-day incubation period. TTD analysis was based only on the corresponding qualitative sputum results of pure positive and pure negative cultures in days and hours of the initial positive signal for a culture from the MGIT printout. Mean change is reported for Baseline, Week 1, Week 2, Week 3, Week 24, Week 26, and Last visit (Month 18 or last visit for participants treated beyond Month 18). (NCT01424670)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 24, Week 26, and Last visit (Month 18 or last visit for participants treated beyond Month 18)

Proportion of Participants With Final Outcome At Month 30 As A Treatment Success Or Failure (Including Relapse) Using MGIT

Intervention	days (Mean)
	At Baseline	At Week 1	Change from Baseline at Week 1	At Week 2	Change from Baseline at Week 2	At Week 3	Change from Baseline at Week 3	At Week 24	Change from Baseline at Week 24	At Week 26	Change from Baseline at Week 26	At Last Visit	Change from Baseline at Last Visit
Delamanid + OBR	16.7	20.8	4.3	24.6	7.7	28.4	11.6	40.4	23.4	40.6	23.8	39.4	22.7
Placebo + OBR	15.4	19.9	4.8	23.1	7.5	25.5	10.4	41.3	25.5	40.5	24.6	40.3	24.9

Treatment success was defined as achieving SCC by 6 months using MGIT, completing the trial out to 30 months with sustained SCC and alive at the last contact for follow-up. All other participants were treatment failures who failed to achieve SCC by Month 6, achieved SCC but have a confirmed positive, early terminate from the trial prior to the Month 30 visit but are alive at the last contact for follow-up, lost to follow-up and vital status unknown and death. (NCT01424670)
Timeframe: Month 30

Proportion of Participants With SCC At 2 And 6 Months Using MGIT

Intervention	Participants (Count of Participants)
	Success	Failure
Delamanid + OBR	173	53
Placebo + OBR	78	23

"SCC was evaluated at 2 and 6 months (6-month Intensive Period) using MGIT. SCC at 2 months was defined to occur at the date of collection of the first sputum specimen with mycobacterial culture negative for growth of MTB using MGIT culture, followed by at least 1 confirmatory negative MGIT culture result at least 25 days after the first negative specimen and not followed by any sputum specimens positive for growth in the MGIT culture at any point up to 3 months (Week 12).~SCC at 6 months was determined by the observation of a sputum specimen negative for growth of MTB using the MGIT culture system, followed by at least 1 confirmatory negative sputum culture at least 25 days after the first negative and not followed by a confirmed positive (defined as at least 2 observed positive results, not taking into account indeterminate, missing, or contaminated results). 2 specimens were collected at each visit and an algorithm in the SAP was used to define a single representative result." (NCT01424670)
Timeframe: Month 2 and Month 6

Proportion of Participants With Sustained SCC At Month 18, Month 24, And Month 30 Using MGIT

Intervention	Participants (Count of Participants)
	At Month 2	At Month 6
Delamanid + OBR	132	198
Placebo + OBR	54	87

Sustained SCC was defined as SCC achieved by Month 6 and not followed by a confirmed positive thereafter, where confirmed positive was defined as 2 or more observed positive single representative culture results, not taking into account indeterminate, missing, or contaminated results. Sustained SCC was analyzed at Month 18 to 30 using MGIT. (NCT01424670)
Timeframe: Month 18, Month 24, and Month 30

Percentage of Participants Who Discontinue Due to an Adverse Event in Each Experimental Arm.

Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Liquid Media

Intervention	Participants (Count of Participants)
	At 18 months	At 24 months	At 30 months
Delamanid + OBR	180	178	173
Placebo + OBR	83	82	78

Intervention	percentage of participants (Number)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	13
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	19
Drug Sensitive: Rifafour	12
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	12

Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. This was measured at visit 24(Day 57). (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment

Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Solid Media

Intervention	percentage of patients (Number)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	65.7
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	71.4
Drug Sensitive: Rifafour	37.8
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	50.0

Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. (Day 57) (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment

The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment.

Intervention	percentage of participants (Number)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	82.9
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	94.3
Drug Sensitive: Rifafour	87.5
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	62.5

The primary efficacy endpoint was bactericidal activity characterized by the daily rate of change in mean log10CFU counts during 8 weeks of treatment (bactericidal activity assessed by CFU on solid media for days 0-56). (NCT01498419)
Timeframe: 8 weeks

The Rate of Change in Time to Sputum Culture Positivity (TTP) Through 8 Weeks in the MGIT System in Sputum Over 8 Weeks in Participants as Derived From a Non-linear Regression Model.

Intervention	log10CFU/ml/day (Mean)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	0.133
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	0.155
Drug Sensitive: Rifafour	0.112
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	0.117

Measurement of TTP in liquid culture media Mycobacteria growth indicator tube (MGIT) using standard procedures (NCT01498419)
Timeframe: 8 weeks

Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Liquid Media

Intervention	log10hours/day (Mean)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	0.020
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	0.020
Drug Sensitive: Rifafour	0.017
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	0.015

liquid culture = Mycobacteria growth indicator tube (MGIT) Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks

Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Solid Media

Intervention	days (Median)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	42.0
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	49.0
Drug Sensitive: Rifafour	56.0
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	56.0

Proportion of Participants Who Accepted 3HP Treatment

Intervention	days (Median)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)	28.0
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)	28.0
Drug Sensitive: Rifafour	35.0
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)	35.0

The count of eligible people living with HIV (PLHIV) offered 3HP who accept to initiate treatment (by age, gender, CD4 stratum, viral load suppression) divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation

Proportion of Participants Who Accepted and Completed 3HP

Intervention	proportion of participants (Number)
Facilitated Directly Observed Therapy (DOT)	0.998
Facilitated Self-Administered Therapy (SAT)	1.00
Patient Choice Between Facilitated DOT and Facilitated SAT	0.995

The count of eligible participants who accept treatment and take at least 11 of 12 once weekly doses of rifapentine (RPT)/isoniazid (INH) within 16 weeks of treatment initiation divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation

Proportion of Participants Who Completed 3HP Treatment

Intervention	proportion of participants (Number)
Facilitated Directly Observed Therapy (DOT)	0.946
Facilitated Self-Administered Therapy (SAT)	0.922
Patient Choice Between Facilitated DOT and Facilitated SAT	0.944

Count of participants who take at least 11 of 12 doses within 16 weeks of treatment initiation divided by the count those who take at least one dose of 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation

Proportion of People Who Discontinued 3HP Treatment Due to Adverse Events/Intolerance

Intervention	proportion of participants (Number)
Facilitated Directly Observed Therapy (DOT)	0.947
Facilitated Self-Administered Therapy (SAT)	0.922
Patient Choice Between Facilitated DOT and Facilitated SAT	0.949

Count of participants for whom treatment is discontinued due to adverse events or intolerance divided by the count of those who initiated 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation

Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity

Intervention	proportion of participants (Number)
Facilitated Directly Observed Therapy (DOT)	0.0054
Facilitated Self-Administered Therapy (SAT)	0.013
Patient Choice Between Facilitated DOT and Facilitated SAT	0.0073

Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Number of Participants Who Discontinued Treatment

Intervention	percent (Number)
INH and Vitamin B6	8.3

Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Number of Participants With Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Elevations at Study Screening

Intervention	Participants (Count of Participants)
INH and Vitamin B6	32

Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit

Number of Participants With Latent Tuberculosis at Study Screening.

Intervention	Participants (Count of Participants)
Study Screening	80

Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit

INH Concentration in Hair: (INH Pmol + Acetyl INH Pmol) Per mg of Hair

Intervention	Participants (Count of Participants)
Study Screening	308

INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation

Percentage of Participants With Suboptimal INH Medication Adherence

Intervention	pmol/mg (Median)
	at 3 months	at 6 months
INH and Vitamin B6	36.0	37.8

Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)

Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days

Intervention	percentage of participants (Number)
	at 3 months	at 6 months
INH and Vitamin B6	31.3	43.9

"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH

Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale

Intervention	days (Median)
	at 3 months	at 6 months
INH and Vitamin B6	30	30

The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH

Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.

Intervention	Participants (Count of Participants)
	At 3 months72558043	At 6 months72558043
	Excellent	Very good	Good	Fair	Poor	Very poor
INH and Vitamin B6	160
INH and Vitamin B6	79
INH and Vitamin B6	38
INH and Vitamin B6	2
INH and Vitamin B6	124
INH and Vitamin B6	90
INH and Vitamin B6	41
INH and Vitamin B6	4
INH and Vitamin B6	0
INH and Vitamin B6	1

Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group. (NCT03028129)
Timeframe: up to 6 months

Reviews

Trials

Other Studies

1014 other studies available for isoniazid and Tuberculosis, Multidrug-Resistant

Authors	Studies
Andries, K	2
Verhasselt, P	1
Guillemont, J	1
Göhlmann, HW	1
Neefs, JM	1
Winkler, H	1
Van Gestel, J	1
Timmerman, P	1
Zhu, M	1
Lee, E	1
Williams, P	1
de Chaffoy, D	1
Huitric, E	1
Hoffner, S	16
Cambau, E	2
Truffot-Pernot, C	4
Lounis, N	1
Jarlier, V	3
Gegia, M	1
Mdivani, N	1
Mendes, RE	1
Li, H	5
Akhalaia, M	1
Han, J	2
Khechinashvili, G	2
Tang, YW	2
Luo, T	2
Zhao, M	3
Li, X	3
Xu, P	4
Gui, X	1
Pickerill, S	1
DeRiemer, K	2
Mei, J	2
Gao, Q	5
Krátký, M	4
Vinšová, J	5
Buchta, V	1
Horvati, K	3
Bösze, S	4

Article	Year
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. European journal of medicinal chemistry, 2014, Oct-30, Volume: 86 Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship;	2014
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. European journal of medicinal chemistry, 2014, Oct-30, Volume: 86 Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship;	2014
Isoniazid derivatives and their anti-tubercular activity. European journal of medicinal chemistry, 2017, Jun-16, Volume: 133 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber	2017
Isoniazid derivatives and their anti-tubercular activity. European journal of medicinal chemistry, 2017, Jun-16, Volume: 133 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber	2017
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Antitubercular Agents; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Lactones	2021
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Antitubercular Agents; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Lactones	2021
Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis. PloS one, 2021, Volume: 16, Issue:10 Topics: Ethiopia; Humans; Isoniazid; Prevalence; Rifampin; Risk Factors; Tuberculosis, Multidrug-Resistant	2021
Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis. PloS one, 2021, Volume: 16, Issue:10 Topics: Ethiopia; Humans; Isoniazid; Prevalence; Rifampin; Risk Factors; Tuberculosis, Multidrug-Resistant	2021
Combining LAMP and Au-Nanoprobe to detect INH-RIF resistance accurately in tuberculosis: an evidence-based review. Journal of infection in developing countries, 2021, 11-30, Volume: 15, Issue:11 Topics: Antibiotics, Antitubercular; DNA, Bacterial; Humans; Isoniazid; Molecular Diagnostic Techniques; Nuc	2021
Combining LAMP and Au-Nanoprobe to detect INH-RIF resistance accurately in tuberculosis: an evidence-based review. Journal of infection in developing countries, 2021, 11-30, Volume: 15, Issue:11 Topics: Antibiotics, Antitubercular; DNA, Bacterial; Humans; Isoniazid; Molecular Diagnostic Techniques; Nuc	2021
MDR Tuberculosis Treatment. Medicina (Kaunas, Lithuania), 2022, Jan-26, Volume: 58, Issue:2 Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multid	2022
MDR Tuberculosis Treatment. Medicina (Kaunas, Lithuania), 2022, Jan-26, Volume: 58, Issue:2 Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multid	2022
Drug resistant TB - latest developments in epidemiology, diagnostics and management. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022, Volume: 124 Suppl 1 Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tub	2022
Drug resistant TB - latest developments in epidemiology, diagnostics and management. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022, Volume: 124 Suppl 1 Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tub	2022
Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Tuberculosis (Edinburgh, Scotland), 2022, Volume: 135 Topics: Antitubercular Agents; Drug Resistance; Ethambutol; Humans; Isoniazid; Lasers; Microbial Sensitivity	2022
Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Tuberculosis (Edinburgh, Scotland), 2022, Volume: 135 Topics: Antitubercular Agents; Drug Resistance; Ethambutol; Humans; Isoniazid; Lasers; Microbial Sensitivity	2022
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. The Cochrane database of systematic reviews, 2022, 05-18, Volume: 5 Topics: Adult; Amikacin; Antibiotics, Antitubercular; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolo	2022
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. The Cochrane database of systematic reviews, 2022, 05-18, Volume: 5 Topics: Adult; Amikacin; Antibiotics, Antitubercular; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolo	2022
Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis. Clinica chimica acta; international journal of clinical chemistry, 2022, Aug-01, Volume: 533 Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Microbial Sensiti	2022
Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis. Clinica chimica acta; international journal of clinical chemistry, 2022, Aug-01, Volume: 533 Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Microbial Sensiti	2022
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives. Clinical microbiology reviews, 2022, 12-21, Volume: 35, Issue:4 Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis, Mult	2022
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives. Clinical microbiology reviews, 2022, 12-21, Volume: 35, Issue:4 Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis, Mult	2022
[Treatment of tuberculosis: what is new?] Innere Medizin (Heidelberg, Germany), 2023, Volume: 64, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Mu	2023
[Treatment of tuberculosis: what is new?] Innere Medizin (Heidelberg, Germany), 2023, Volume: 64, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Mu	2023
Multi-drug resistant and rifampin-resistant tuberculosis in transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society, 2023, Volume: 25, Issue:4 Topics: Adolescent; Adult; Female; Humans; Isoniazid; Male; Middle Aged; Rifampin; Transplant Recipients; Tu	2023
Multi-drug resistant and rifampin-resistant tuberculosis in transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society, 2023, Volume: 25, Issue:4 Topics: Adolescent; Adult; Female; Humans; Isoniazid; Male; Middle Aged; Rifampin; Transplant Recipients; Tu	2023
Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis. PloS one, 2023, Volume: 18, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-R	2023
Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis. PloS one, 2023, Volume: 18, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-R	2023
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. Journal of infection and public health, 2023, Volume: 16, Issue:9 Topics: Antitubercular Agents; Bacterial Proteins; Chemical and Drug Induced Liver Injury; Drug Resistance,	2023
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. Journal of infection and public health, 2023, Volume: 16, Issue:9 Topics: Antitubercular Agents; Bacterial Proteins; Chemical and Drug Induced Liver Injury; Drug Resistance,	2023
Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings. The Journal of infection, 2019, Volume: 79, Issue:4 Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Geography; Humans; Isoniazid; My	2019
Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings. The Journal of infection, 2019, Volume: 79, Issue:4 Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Geography; Humans; Isoniazid; My	2019
Sources of Multidrug Resistance in Patients With Previous Isoniazid-Resistant Tuberculosis Identified Using Whole Genome Sequencing: A Longitudinal Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 12-17, Volume: 71, Issue:10 Topics: Antitubercular Agents; Humans; Isoniazid; Longitudinal Studies; Microbial Sensitivity Tests; Mycobac	2020
Sources of Multidrug Resistance in Patients With Previous Isoniazid-Resistant Tuberculosis Identified Using Whole Genome Sequencing: A Longitudinal Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 12-17, Volume: 71, Issue:10 Topics: Antitubercular Agents; Humans; Isoniazid; Longitudinal Studies; Microbial Sensitivity Tests; Mycobac	2020
Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development. Chemical biology & drug design, 2020, Volume: 96, Issue:2 Topics: Antitubercular Agents; Benzaldehydes; Drug Development; Glycosides; Humans; Indoles; Isoniazid; Mole	2020
Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development. Chemical biology & drug design, 2020, Volume: 96, Issue:2 Topics: Antitubercular Agents; Benzaldehydes; Drug Development; Glycosides; Humans; Indoles; Isoniazid; Mole	2020
Tuberculosis treatment in children: The changing landscape. Paediatric respiratory reviews, 2020, Volume: 36 Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is	2020
Tuberculosis treatment in children: The changing landscape. Paediatric respiratory reviews, 2020, Volume: 36 Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is	2020
The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis. Annals of palliative medicine, 2020, Volume: 9, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Dia	2020
The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis. Annals of palliative medicine, 2020, Volume: 9, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Dia	2020

Article	Year
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (New York, N.Y.), 2005, Jan-14, Volume: 307, Issue:5707 Topics: Amino Acid Sequence; Animals; Antitubercular Agents; Bacterial Proton-Translocating ATPases; Diarylq	2005
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (New York, N.Y.), 2005, Jan-14, Volume: 307, Issue:5707 Topics: Amino Acid Sequence; Animals; Antitubercular Agents; Bacterial Proton-Translocating ATPases; Diarylq	2005
Treatment Strategy for Rifampin-Susceptible Tuberculosis. The New England journal of medicine, 2023, Mar-09, Volume: 388, Issue:10 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Et	2023
Treatment Strategy for Rifampin-Susceptible Tuberculosis. The New England journal of medicine, 2023, Mar-09, Volume: 388, Issue:10 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Et	2023
Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance. PloS one, 2019, Volume: 14, Issue:8 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Isonia	2019
Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance. PloS one, 2019, Volume: 14, Issue:8 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Isonia	2019
Clinical predictors of drug-resistant tuberculosis in Mexico. PloS one, 2019, Volume: 14, Issue:8 Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Male; Mexico; Middle Aged; Mycobacterium tu	2019
Clinical predictors of drug-resistant tuberculosis in Mexico. PloS one, 2019, Volume: 14, Issue:8 Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Male; Mexico; Middle Aged; Mycobacterium tu	2019
Transmissibility and potential for disease progression of drug resistant BMJ (Clinical research ed.), 2019, 10-24, Volume: 367 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Disease Pr	2019
Transmissibility and potential for disease progression of drug resistant BMJ (Clinical research ed.), 2019, 10-24, Volume: 367 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Disease Pr	2019
Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. International journal of environmental research and public health, 2021, 03-14, Volume: 18, Issue:6 Topics: Antitubercular Agents; Cohort Studies; Humans; Isoniazid; Prospective Studies; Rifampin; Treatment O	2021
Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. International journal of environmental research and public health, 2021, 03-14, Volume: 18, Issue:6 Topics: Antitubercular Agents; Cohort Studies; Humans; Isoniazid; Prospective Studies; Rifampin; Treatment O	2021
HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients. Scientific reports, 2017, 04-13, Volume: 7 Topics: Adult; Aged; Aged, 80 and over; Female; Glycated Hemoglobin; HIV; Humans; Isoniazid; Male; Middle Ag	2017
HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients. Scientific reports, 2017, 04-13, Volume: 7 Topics: Adult; Aged; Aged, 80 and over; Female; Glycated Hemoglobin; HIV; Humans; Isoniazid; Male; Middle Ag	2017
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. JAMA internal medicine, 2018, 04-01, Volume: 178, Issue:4 Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Directly Observed Therapy; Drug	2018
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. JAMA internal medicine, 2018, 04-01, Volume: 178, Issue:4 Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Directly Observed Therapy; Drug	2018
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. The Lancet. Infectious diseases, 2019, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Substitution; Drug Therapy, Combination;	2019
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. The Lancet. Infectious diseases, 2019, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Substitution; Drug Therapy, Combination;	2019
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014. PloS one, 2018, Volume: 13, Issue:12 Topics: Adolescent; Adult; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Etha	2018
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014. PloS one, 2018, Volume: 13, Issue:12 Topics: Adolescent; Adult; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Etha	2018
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:3 Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Ther	2019
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:3 Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Ther	2019
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, Sep-09, Volume: 15 Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Dr	2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, Sep-09, Volume: 15 Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Dr	2014
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10 Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol	2014
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10 Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol	2014
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethamb	2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethamb	2015
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011
New regimens to prevent tuberculosis in adults with HIV infection. The New England journal of medicine, 2011, Jul-07, Volume: 365, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o	2011

Article	Year
Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:2 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Ethambutol; Georgia	2008
Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:2 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Ethambutol; Georgia	2008
Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Antitubercular Agents; Bacterial Proteins; China; Cohort Studies; Culture Media; Drug Resistance, Mu	2010
Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Antitubercular Agents; Bacterial Proteins; China; Cohort Studies; Culture Media; Drug Resistance, Mu	2010
New amino acid esters of salicylanilides active against MDR-TB and other microbes. European journal of medicinal chemistry, 2010, Volume: 45, Issue:12 Topics: Amino Acids; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; D	2010
New amino acid esters of salicylanilides active against MDR-TB and other microbes. European journal of medicinal chemistry, 2010, Volume: 45, Issue:12 Topics: Amino Acids; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; D	2010
New fluorine-containing hydrazones active against MDR-tuberculosis. European journal of medicinal chemistry, 2011, Volume: 46, Issue:10 Topics: Animals; Antitubercular Agents; Cell Line; Fluorine; Humans; Hydrazones; Microbial Sensitivity Tests	2011
New fluorine-containing hydrazones active against MDR-tuberculosis. European journal of medicinal chemistry, 2011, Volume: 46, Issue:10 Topics: Animals; Antitubercular Agents; Cell Line; Fluorine; Humans; Hydrazones; Microbial Sensitivity Tests	2011
Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives. Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: Antitubercular Agents; China; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oligo	2011
Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives. Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: Antitubercular Agents; China; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oligo	2011
Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues. Bioorganic & medicinal chemistry letters, 2012, Jan-15, Volume: 22, Issue:2 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Microbial Se	2012
Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues. Bioorganic & medicinal chemistry letters, 2012, Jan-15, Volume: 22, Issue:2 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Microbial Se	2012
Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters, 2012, Apr-15, Volume: 22, Issue:8 Topics: Alkaloids; Antitubercular Agents; Benzylisoquinolines; Drug Resistance, Multiple, Bacterial; Humans;	2012
Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters, 2012, Apr-15, Volume: 22, Issue:8 Topics: Alkaloids; Antitubercular Agents; Benzylisoquinolines; Drug Resistance, Multiple, Bacterial; Humans;	2012
2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis. European journal of medicinal chemistry, 2014, Apr-22, Volume: 77 Topics: Animals; Antitubercular Agents; Cell Line; Dose-Response Relationship, Drug; Isoquinolines; Macropha	2014
2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis. European journal of medicinal chemistry, 2014, Apr-22, Volume: 77 Topics: Animals; Antitubercular Agents; Cell Line; Dose-Response Relationship, Drug; Isoquinolines; Macropha	2014
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent. Journal of medicinal chemistry, 2014, Jun-26, Volume: 57, Issue:12 Topics: Animals; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Imidazoles; Macrophage	2014
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent. Journal of medicinal chemistry, 2014, Jun-26, Volume: 57, Issue:12 Topics: Animals; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Imidazoles; Macrophage	2014
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates. Bioorganic & medicinal chemistry, 2015, Feb-15, Volume: 23, Issue:4 Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Benzoates; Fungi; Humans;	2015
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates. Bioorganic & medicinal chemistry, 2015, Feb-15, Volume: 23, Issue:4 Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Benzoates; Fungi; Humans;	2015
Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design. European journal of medicinal chemistry, 2015, Jul-15, Volume: 100 Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Drug Repositio	2015
Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design. European journal of medicinal chemistry, 2015, Jul-15, Volume: 100 Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Drug Repositio	2015
Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates. European journal of medicinal chemistry, 2015, Aug-28, Volume: 101 Topics: Anti-Bacterial Agents; Carbamates; Cell Line; Dose-Response Relationship, Drug; Esters; Humans; Micr	2015
Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates. European journal of medicinal chemistry, 2015, Aug-28, Volume: 101 Topics: Anti-Bacterial Agents; Carbamates; Cell Line; Dose-Response Relationship, Drug; Esters; Humans; Micr	2015
Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecu	2015
Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecu	2015
Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety. European journal of medicinal chemistry, 2015, Nov-02, Volume: 104 Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterococcus; Fluoroquinolones; Microbial S	2015
Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety. European journal of medicinal chemistry, 2015, Nov-02, Volume: 104 Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterococcus; Fluoroquinolones; Microbial S	2015
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents. European journal of medicinal chemistry, 2015, Dec-01, Volume: 106 Topics: Animals; Antitubercular Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Stab	2015
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents. European journal of medicinal chemistry, 2015, Dec-01, Volume: 106 Topics: Animals; Antitubercular Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Stab	2015
Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase. European journal of medicinal chemistry, 2015, Dec-01, Volume: 106 Topics: Animals; Antitubercular Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitor	2015
Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase. European journal of medicinal chemistry, 2015, Dec-01, Volume: 106 Topics: Animals; Antitubercular Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitor	2015
Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. Bioorganic & medicinal chemistry letters, 2016, May-01, Volume: 26, Issue:9 Topics: Animals; Antitubercular Agents; Cell Line; Cyclic N-Oxides; Drug Resistance, Multiple, Bacterial; La	2016
Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. Bioorganic & medicinal chemistry letters, 2016, May-01, Volume: 26, Issue:9 Topics: Animals; Antitubercular Agents; Cell Line; Cyclic N-Oxides; Drug Resistance, Multiple, Bacterial; La	2016
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection. Journal of medicinal chemistry, 2016, 07-14, Volume: 59, Issue:13 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Design; Female; Hum	2016
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection. Journal of medicinal chemistry, 2016, 07-14, Volume: 59, Issue:13 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Design; Female; Hum	2016
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity. Bioorganic & medicinal chemistry, 2017, 02-15, Volume: 25, Issue:4 Topics: Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Microb	2017
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity. Bioorganic & medicinal chemistry, 2017, 02-15, Volume: 25, Issue:4 Topics: Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Microb	2017
QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity. European journal of medicinal chemistry, 2017, Sep-08, Volume: 137 Topics: Animals; Antitubercular Agents; Chalcone; Chlorocebus aethiops; Dose-Response Relationship, Drug; Dr	2017
QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity. European journal of medicinal chemistry, 2017, Sep-08, Volume: 137 Topics: Animals; Antitubercular Agents; Chalcone; Chlorocebus aethiops; Dose-Response Relationship, Drug; Dr	2017